Expand MYGN Menu
MYGN MENU

MYGN Latest Press Releases

-- June 23, 2026 --

Myriad Genetics Expands Availability of Precise MRD for Colorectal, Renal and Breast Cancers, Supported by New Publication Globe Newswire 9:05 AM

-- June 2, 2026 --

Myriad Genetics Names Raj Jampa as New Chief Technology Officer Globe Newswire 9:05 AM

-- May 27, 2026 --

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting Globe Newswire 9:05 AM

-- May 26, 2026 --

Myriad Genetics Launches Prolaris + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) Globe Newswire 4:05 PM

-- May 15, 2026 --

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life Globe Newswire 11:00 AM

-- May 7, 2026 --

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences Globe Newswire 4:05 PM

-- May 5, 2026 --

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business Globe Newswire 4:05 PM

-- April 30, 2026 --

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan Globe Newswire 9:05 AM

-- April 28, 2026 --

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 Globe Newswire 4:05 PM

-- April 16, 2026 --

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 Globe Newswire 9:15 AM

-- April 14, 2026 --

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan Globe Newswire 9:15 AM

-- April 9, 2026 --

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting Globe Newswire 9:15 AM

-- March 17, 2026 --

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer Globe Newswire 4:05 PM

-- March 6, 2026 --

Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 PRNewswire 6:40 PM

-- March 2, 2026 --

Myriad Commercially Launches Precise MRD with Select Community Oncologists Globe Newswire 4:05 PM

-- February 24, 2026 --

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk tests Globe Newswire 9:00 AM
Diality Appoints Peter Donato as Chief Financial Officer Business Wire 7:05 AM

-- February 23, 2026 --

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Globe Newswire 4:05 PM

-- February 19, 2026 --

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test Globe Newswire 9:15 AM

-- February 16, 2026 --

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 Globe Newswire 4:15 PM
Market Data Delayed 15 Minutes